The MarketWatch News Department was not involved in the creation of this content. First English-language case study shows resolution of lesions with 308-nm Excimer laser in rare mycosis fungoides (MF) ...

In the last few years, there have been scattered reports linking dupilumab with mycosis fungoides. A recent study from the Journal of the American Academy of Dermatology reported a systematic review ...

Mycosis fungoides is the most common type of cutaneous T-cell lymphoma. This rare form of cancer occurs when the germ-fighting cells of the immune system (T-cells) begin to attack a person’s skin.

Please provide your email address to receive an email when new articles are posted on . Treatment with synthetic hypericin produced significant index lesion response in patients with early-stage ...

Lacutamab is a first-in-class anti-KIR3DL2 humanized cytotoxicity-inducing antibody that is currently in clinical trials for treatment of cutaneous T-cell lymphoma (CTCL), an orphan disease, and ...

The mycosis fungoides market is anticipated to progress steadily, influenced by the relatively small pipeline of emerging therapies. Leading candidates such as Soligenix's HYBRYTE and Innate Pharma's ...

Cutaneous T cell lymphomas (CTCL) represent a heterogeneous group of T-cell malignancies that manifest primarily in the skin. By far the most common variant of CTCL is mycosis fungoides and its ...

MARSEILLE, France--(BUSINESS WIRE)--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) announced favorable results from the Phase 2 TELLOMAK study with ...

Please provide your email address to receive an email when new articles are posted on . Chlormethine gel showed efficacy in combination with corticosteroids or other treatments such as phototherapy in ...

(MENAFN- EIN Presswire) EINPresswire/ -- The Folliculotropic Mycosis Fungoides Treatment Market is entering a decisive decade of transformation as manufacturers race to address the rising clinical ...

First English-language case study shows resolution of lesions with 308-nm Excimer laser in rare mycosis fungoides (MF) subtype, poikilodermatous mycosis fungiodes (pMF), underscoring the Company’s ...

The cause of mycosis fungoides is unknown and, with the possible exception of very early stage disease, no cure is available. Fortunately, patients with MF have a number of therapeutic options and ...